Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,918 GBX | +2.02% | -1.51% | +7.24% |
Mar. 11 | FTSE 100 Closes Up 0.12% Ahead of U.K. Jobs Data | DJ |
Mar. 06 | The FTSE 100 Closed Up 0.4% as U.K. Announces Spring Budget Tax Cuts | DJ |
Business Summary
- generic injectable products (45.3%);
- brand name drugs (27.5%);
- generic products taken orally (26.7%);
- other (0.5%).
Net sales are distributed geographically as follows: the United Kingdom (0.3%), the United States (56.9%), Middle East and North Africa (34.4%) and other (8.4%).
Number of employees: 9,100
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Injectables
41.8
%
| 926 | 45.3 % | 968 | 41.8 % | +4.48% |
Generics
32.6
%
| 546 | 26.7 % | 754 | 32.6 % | +38.17% |
Branded
24.8
%
| 561 | 27.5 % | 574 | 24.8 % | +2.39% |
Others
0.7
%
| 11 | 0.5 % | 17 | 0.7 % | +60.07% |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
60.0
%
| 1,163 | 56.9 % | 1,389 | 60.0 % | +19.35% |
Middle East and North Africa
12.7
%
| 308 | 15.1 % | 294 | 12.7 % | -4.31% |
Saudi Arabia
9.1
%
| 195 | 9.5 % | 210 | 9.1 % | +7.76% |
Europe and Rest of the World
7.2
%
| 170 | 8.3 % | 166 | 7.2 % | -2.79% |
Algeria
6.6
%
| 107 | 5.2 % | 152 | 6.6 % | +41.88% |
Egypt
3.2
%
| 93 | 4.6 % | 75 | 3.2 % | -19.86% |
North America
0.8
%
| - | - | 19 | 0.8 % | - |
United Kingdom
0.4
%
| 6 | 0.3 % | 9 | 0.4 % | +36.25% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Riad Mishlawi
CEO | Chief Executive Officer | 60 | 89-12-31 |
Khalid Nabilsi
DFI | Director of Finance/CFO | 52 | 00-12-31 |
Said Darwazah
CHM | Chairman | 66 | 80-12-31 |
Mazen Darwazah
BRD | Director/Board Member | 65 | 84-12-31 |
Susan Ringdal
IRC | Investor Relations Contact | - | 05-10-31 |
Kristy Ronco
SAM | Sales & Marketing | - | 18-08-16 |
William Larkins
PRN | Corporate Officer/Principal | - | 21-12-31 |
Hussein Arkhagha
HRO | Human Resources Officer | - | 00-12-31 |
Majda Labadi
PRN | Corporate Officer/Principal | - | 84-12-31 |
Bassam Kanaan
PRN | Corporate Officer/Principal | 58 | 00-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Hurt
BRD | Director/Board Member | 66 | 20-04-30 |
Nina Henderson
BRD | Director/Board Member | 72 | 16-09-30 |
Victoria Hull
BRD | Director/Board Member | 62 | 22-10-31 |
Director/Board Member | 66 | 80-12-31 | |
Mazen Darwazah
BRD | Director/Board Member | 65 | 84-12-31 |
John Castellani
BRD | Director/Board Member | 73 | 16-02-29 |
Said Darwazah
CHM | Chairman | 66 | 80-12-31 |
Cynthia Flowers
BRD | Director/Board Member | 64 | 19-05-31 |
Patrick Butler
BRD | Director/Board Member | 63 | 14-03-31 |
Deneen Vojta
BRD | Director/Board Member | 59 | 22-10-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 234,718,492 | 153,733,558 ( 65.50 %) | 12,833,233 ( 5.467 %) | 65.50 % |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Hikma Ventures Ltd.
Hikma Ventures Ltd. Investment ManagersFinance Hikma Ventures Ltd is a venture capital firm founded in 2015. The firm is headquartered in London, UK. |
Investment Managers
|
Hikma Finance USA LLC
|
Finance/Rental/Leasing
|
Sector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+6.68% | 5.27B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.58% | 210B | |
+1.02% | 210B | |
-6.46% | 201B | |
-3.51% | 157B |
- Stock
- Equities
- Stock Hikma Pharmaceuticals PLC - London S.E.
- Company Hikma Pharmaceuticals PLC